For example, the results of a study that used actuarial methods to compare the estimated lifetime CV, kidney and mortality benefits of the combination of an SGLT2i plus a GLP-1 RA plus finerenone versus conventional therapy (a RAAS inhibitor plus traditional risk factor control) found that the triple combination has the potential to afford more relevant gains in CV and kidney event-free and overall survival in patients with CKD and T2D versus conventional therapy alone [50]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.